InsidersTradesSigma
申报总数
公司
▲ 买入（3 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
3
已披露卖出
0
T+90 胜率
33%
T+90 平均收益
-21.5%
基于 3 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the detailed record of transactions filed by Combs Andrew, 管理人员. Officer active across 1 company, notably Prelude Therapeutics Inc. Aggregated, 4 reports have been logged. Breakdown: 3 buys · 0 sell. Total volume traded: €110k. Activity tracked since 13 December 2021. The latest transaction was disclosed on 25 March 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Combs Andrew
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报4 总计
100,000 股@ US$0.692529.8% 占其流量Common StockSEC:0001562180-25-002779:0
标准退出：2025年6月23日 (T+90)
3,075 股@ US$1.151.6% 占其流量Common StockSEC:0001562180-24-008565:0
标准退出：2025年3月20日 (T+90)
36,062 股@ US$1.8935.8% 占其流量Common StockSEC:0001209191-22-022524:0
4,000 股@ US$12.1224.9% 占其流量Common StockSEC:0001209191-21-069796:0
标准退出：2022年3月13日 (T+90)
4 条申报中的 4 条
About Combs Andrew
Andrew Combs is Executive Vice President and Head of Chemistry at Prelude Therapeutics Inc. He oversees the company's research and development initiatives, focusing on innovation in the therapeutic area.
